Oral semaglutide for Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether an oral (taken by mouth) medication called semaglutide can slow the progression of Alzheimer's disease. Semaglutide is already used for diabetes and weight management, and this trial looks at its potential effect on memory and thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a formal diagnosis of Alzheimer's disease (confirmed by a doctor using standard criteria).
- You are at least 50 years old.
- You have a reliable family member or friend who can accompany you to study visits and help with communication.
- You have a mini-mental test score of 18 or more, meaning you have mild to moderate memory problems but can still participate in assessments.
- You are not currently taking narcotic pain medications that could affect thinking, and you have not had a heart attack within the past year.
- You have no history of medullary thyroid cancer, pancreatitis, or gallstones, and no other significant brain conditions besides Alzheimer's.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a combination of insulin and semaglutide (a diabetes drug) can improve memory and thinking in people with mild cognitive impairment (MCI) who also have metabolic syndrome (a cluster of health issues like large waist, high blood sugar, and high blood pressure). It aims to see if treating blood sugar problems helps protect the brain.
This study tests whether adding a treatment that improves blood vessel and insulin function can make the standard Alzheimer's medication work better for people with mild Alzheimer's or mild cognitive impairment.
This study tests a new way to treat and monitor Alzheimer's disease by closely tracking brain changes. It may help slow down memory loss and improve quality of life.
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
This trial tests if an oral medication called semaglutide can help people with open-angle glaucoma. It aims to see if it can protect the optic nerve and manage eye pressure.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.